Osteoprotegerin as a possible novel predictor of cardiovascular dysfunction

Kardiochirurgia i Torakochirurgia Polska

Volumn 9, Issue 1, 2012, Pages 82-85

  Stȩpień, Ewa ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Bone remodelling biomarkers; Cardiovascular diseases; Dendritic cells; Inflammation; Osteoprotegerin

Indexed keywords

EID: 84860186055     PISSN: 17315530     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, Nishizawa Y. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002; 106: 1192-1194. (Pubitemid 34988634)
2. Di Bartolo BA, Schoppet M, Mattar MZ, Rachner TD, Shanahan CM, Kavurma MM. Calcium and osteoprotegerin regulate IGF1R expression to inhibit vascular calcification. Cardiovasc Res 2011; 91: 537-545.
3. Stȩpień E Acceleration of new biomarkers development and discovery in synergistic diagnostics of coronary artery disease. In: Coronary Angiography. Book 2. Editor B. Baskot. In Tech Open Access Publisher 2011.
4. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004; 109: 2175-2180. (Pubitemid 38625393)
5. Siepi D, Marchesi S, Vaudo G, Lupattelli G, Bagaglia F, Pirro M, Brozzetti M, Roscini AR, Mannarino E. Preclinical vascular damage in white postmenopausal women: the relevance of osteoprotegerin. Metabolism 2008; 57: 321-325. (Pubitemid 351178720)
6. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999; 96: 3540-3545. (Pubitemid 29168945)
7. Zauli G, Melloni E, Capitani S, Secchiero P. Role of full-length osteoprotegerin in tumor cell biology. Cell Mol Life Sci 2009; 66: 841-851.
8. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, Di Prinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273: 14363-14367. (Pubitemid 28319153)
9. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS. Osteoprotegerin deficient mice develop early onset osteoporosis and arterial calcification. Genes Develop 1998; 12: 1260-1268. (Pubitemid 28213402)
10. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000; 92: 463-474. (Pubitemid 30666247)
11. Vik A, Mathiesen EB, Brox J, Wilsgaard T, Njølstad I, Jørgensen L, Hansen JB. Relation between serum osteoprotegerin and carotid intima media thickness in a general population - the Tromsø Study. J Thromb Haemost 2010; 8: 2133-2139.
12. Vik A, Mathiesen EB, Brox J, Wilsgaard T, Njølstad I, Jørgensen L, Hansen JB. Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population - The Tromsø Study. J Thromb Haemost 2011; 9: 638-644.
13. Ashley DT, O'Sullivan EP, Davenport C, Devlin N, Crowley RK, McCaffrey N, Moyna NM, Smith D, O'Gorman DJ. Similar to adiponectin, serum levels of osteoprotegerin are associated with obesity in healthy subjects. Metabolism 2011; 60: 994-1000.
14. Jørgensen L, Hansen JB, Brox J, Mathiesen E, Vik A, Jacobsen BK. Serum osteoprotegerin levels are related to height loss: the Tromsø Study. Eur J Epidemiol 2011; 26: 305-312.
15. Anand DV, Lahiri A, Lim E, Hopkins D, Corder R. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 2006; 47: 1850-1857.
16. Blázquez-Medela AM, García-Ortiz L, Gómez-Marcos MA, Recio-Rodriguez JI, Sánchez-Rodríguez A, López-Novoa JM, Martínez-Salgado C. Osteoprotegerin is associated with cardiovascular risk in hypertension and/or diabetes. Eur J Clin Invest 2011 Oct. 14. doi: 10.1111/j.1365-2362.2011.02619.x.
17. Stȩpień E, Wypasek E, Stopyra K, Konieczyńska M, Przybyło M, Pasowicz M. Increased levels of bone remodeling biomarkers (osteoprotegerin and osteopontin) in hypertensive individuals. Clin Biochem 2011; 44: 826-831.
18. Stȩpień E, Fedak D, Klimeczek P, Wilkosz T, Banyś RP, Starzyk K, Bazanek M, Pasowicz M. Osteoprotegerin but not osteopontin as a potential predictor of vascular calcification in normotensive subjects. Hypertension Res 2012; Jan 26. doi: 10.1038/hr.2011.231.
19. Abedin M, Omland T, Ueland T, Khera A, Aukrust P, Murphy SA, Jain T, Gruntmanis U, McGuire DK, de Lemos JA. Relation of osteoprotegerin to coro-nary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol 2007; 99: 513-518. (Pubitemid 46215559)
20. Olesen, P, Ledet T, Rasmussen LM. Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-α. Diabetologia 2005; 48: 561-568. (Pubitemid 40487304)
21. Kramer I, Halleux C, Keller H, Pegurri M, Gooi JH, Weber PB, Feng JQ, Bonewald LF, Kneissel M. Osteocyte Wnt/β-catenin signaling is required for normal bone homeostasis. Mol Cell Biol 2010; 30: 3071-3085.
22. Zauli G, Corallini F, Bossi F, Fischetti F, Durigutto P, Celeghini C, Tedesco F, Secchiero P. Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood 2007; 110: 536-543. (Pubitemid 47105391)
23. Moran CS, Cullen B, Campbell JH, Golledge J. Interaction between angiotensin II, osteoprotegerin, and peroxisome proliferator-activated receptorgamma in abdominal aortic aneurysm. J Vasc Res 2009; 46: 209-217.
24. Zhang J, Fu M, Myles D, Zhu X, Du J, Cao X, Chen YE. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett 2002; 521: 180-184. (Pubitemid 34628481)
25. Burton DG, Giles PJ, Sheerin AN, Smith SK, Lawton JJ, Ostler EL, Rhys-Williams W, Kipling D, Faragher RG. Microarray analysis of senescent vascular smooth muscle cells: A link to atherosclerosis and vascular calcification. Exp Gerontol 2009; 44: 659-665.
26. Zauli G, Melloni E, Capitani S, Secchiero P. Role of full-length osteoprotegerin in tumor cell biology. Cell Mol Life Sci 2009; 66: 841-851.
27. Yamada A, Takami M, Kawawa T, Yasuhara R, Zhao B, Mochizuki A, Miyamoto Y, Eto T, Yasuda H, Nakamichi Y, Kim N, Katagiri T, Suda T, Kamijo R. Interleukin-4 inhibition of osteoclast differentiation is stronger than that of interleukin-13 and they are equivalent for induction of osteoprotegerin production from osteoblasts. Immunology 2007; 120: 573-579. (Pubitemid 46365017)
28. Wong BR, Josien R, Lee SY, Sauter B, Li HL, Steinman RM, Choi Y. TRANCE (tumor necrosis factor TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cellspecific survival factor. J Exp Med 1997; 186: 2075-2080. (Pubitemid 28013694)
29. Toffoli B, Pickering RJ, Tsorotes D, Koitka A, Sheehy K, Bernardi S, Toffoli B, Nguyen-Huu TP, Head GA, Fu Y, Chin-Dusting J, Cooper ME, Tikellis C. Osteoprotegerin promotes vascular fibrosis via a TGF-β1 autocrine loop. Atherosclerosis 2011; 218: 61-68.
30. Chino T, Draves KE, Clark EA. Regulation of dendritic cell survival and cytokine production by osteoprotegerin. J Leukoc Biol 2007; 86: 933-940.
31. Bennett BJ, Scatena M, Kirk EA, Rattazzi M, Varon RM, Averill M, Schwartz SM, Giachelli CM, Rosenfeld ME. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older Apo E-/-mice. Arterioscler Thromb Vasc Biol 2006; 26: 2117-2124. (Pubitemid 44253797)
32. Morony S, Tintut Y, Zhang Z, Cattley RC, Van G, Dwyer D, Stolina M, Kostenuik PJ, Demer LL. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation 2008; 117: 411-420.
33. Quercioli A, Luciano Viviani G, Dallegri F, Mach F, Montecucco F. Receptor activator of nuclear factor kappa B ligand/osteoprotegerin pathway is a promising target to reduce atherosclerotic plaque calcification. Crit Pathw Cardiol 2010; 9: 227-230.